CEVEC Raises €6M to Grow CAP Technology Based Protein and Vaccine Business
The CAP ® Technology platform comprises human CAP® and CAP-T™ expression systems and is used for the manufacture of complex biologics and therapeutic antibodies with human-like glycosylation and sialylation patterns. New data proved that the human CAP ® technology is also an excellent platform for various vaccine production needs. Outstanding data obtained with the only independent available human cell system for various influenza strains and various other vaccine types show the broad range where the CAP system can be used.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.